Price
No data yet.
Social Signal Score
Analyst Ratings
14 analystsRevenue
$41.24M+9261.63%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Christian Martin Itin
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 752
- Beta
- 2.35
- Country
- GB
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -4.23
Financials
Revenue
$41.24M+9261.6%Net Income
$-55.09MEBITDA
$-41.05MFree Cash Flow
$-19.78MEPS (diluted)
$-0.21Shares Outstanding (diluted)
266.20M+2169.1%Operating Expenses
$66.85MCash & Debt
$248.38MReturn of Capital
$0.00Revenue by Segment (annual)
$75.39MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $75.56M | $-288.20M | $-1.08 |
| 2024 | $10.12M | $-220.66M | $-0.87 |
| 2023 | $1.70M | $-208.38M | $-1.20 |
| 2022 | $6.19M | $-148.84M | $-1.57 |
| 2021 | $1.51M | $-142.10M | $-1.97 |
| 2020 | $1.72M | $-142.09M | $-2.76 |
| 2019 | $2.91M | $-123.85M | $-2.88 |
| 2017 | $1.05M | $-31.11M | $-0.99 |
| 2016 | $1.69M | $-19.73M | $-1.43 |
| 2015 | $1.21M | $-12.55M | $-0.91 |
| 2014 | $94.1K | $-7.46M | $-0.54 |
Valuation
AUTLhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
158+1475.00%Social Signal Score
Mentions (11)
- Newsglobenewswire.com·12d ago·Positive
…ell-tolerated with no ICANS, IEC-HS or Grade ≥3 CRS events observed LONDON and GAITHERSBURG, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced longer-term follow up data from the ongoing CARLYSLE trial, a Phase 1 dose confirmation clinical trial of obe-cel in severe refractory systemic lupus erythematosus (…
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call Transcript Autolus Therapeutics plc (AUTL) Q3 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·12d ago·Neutral
Autolus Therapeutics Q3 Earnings Call Highlights Autolus Therapeutics NASDAQ: AUTL raised its full-year AUCATZYL sales outlook after third-quarter revenue nearly doubled from a year earlier, as the company reported improved manufacturing margins and faster-than-planned treatment center onboarding.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
…uld pre-register using the link at the bottom of this press release LONDON and GAITHERSBURG, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announces its operational and financial results for the third quarter ended September 30, 2026.
View source ↗ - Newsseekingalpha.com·26d ago·Neutral
Autolus Therapeutics: Key Questions For The Near Term Autolus Therapeutics remains a Buy, supported by robust product revenue growth and advancing autoimmune pipeline catalysts. Q2 2026 saw product revenue rise to $45.7M, with net loss narrowing and cash runway extended into Q2 2028 via a $250M credit facility. Key near-term catalyst: preliminary multiple sclerosis data for obe-cel expected in Q1 2027, with lupus nephritis phase 2 data guided for 2028.
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
…026 Financial Results and Host Conference Call on November 10, 2026 LONDON and GAITHERSBURG, Md., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced that the Company will release its third quarter 2026 financial results and operational highlights before open of U.S. markets on Tuesday, November 10, 2026.
View source ↗ - Newszacks.com·48d ago·Positive
All You Need to Know About Autolus Therapeutics (AUTL) Rating Upgrade to Buy Autolus Therapeutics (AUTL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗ - Newsglobenewswire.com·48d ago·Positive
…YSLE Trial at the American College of Rheumatology Convergence 2026 LONDON and GAITHERSBURG, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced the online publication of an abstract submitted to the American College of Rheumatology (ACR) Convergence 2026 meeting being held November 6-11, 2026 in Orlando, Flo…
View source ↗ - Newsglobenewswire.com·74d ago·Negative
… the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis LONDON and GAITHERSBURG, Md., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies and candidates, today announced that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to obecabtagene autoleucel (obe-cel) for the t…
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript Autolus Therapeutics plc (AUTL) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·103d ago·Neutral
Autolus Therapeutics Q2 Earnings Call Highlights Autolus Therapeutics NASDAQ: AUTL reported second-quarter 2026 net product revenue of $45.7 million from sales of AUCATZYL, up from $26.2 million in the first quarter and $20.9 million a year earlier, as the company expanded treatment-center access and continued its commercial launch in the United States and United Kingdom.
View source ↗
Earnings
Wed, Mar 10(in 4 months)
Consensus estimate $-0.17 per share
Typical surprise +3.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.21 vs $-0.21beat
- Tue, Aug 11$-0.15 vs $-0.21beat
- Thu, May 14$-0.27 vs $-0.29beat
- Fri, Mar 27$-0.34 vs $-0.26miss
- Wed, Nov 12$-0.30 vs $-0.23miss
- Tue, Aug 12$-0.18 vs $-0.24beat
Estimates and results for AUTL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AUTL officers and directors.
- Bought
- —
- Sold
- $16k
0 trades
1 trade
- Piccina Cintiasold
99 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AUTL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
